MobiHealth News September 8, 2025
Also, a project developing AI for early periodontal disease detection has received over $1 million in grant funding from the Australian government.
Artrya obtains 510(k) for coronary plaque module AI
ASX-listed Artrya has secured regulatory approval in the United States for its AI-powered module for assessing coronary plaque.
It received the United States Food and Drug Administration’s (FDA) 510(k) clearance for the AI module, which provides near real-time assessment of high-risk plaque from coronary CT angiograms.
The approval followed its recent launch in the US in July. Artrya reportedly targets mid-sized hospital systems; it has recently signed a clinical use deal with Tanner Health and has ongoing integrations in Northeast Georgia Health and Cone Health.
Artrya will also...
Today's Sponsors
Today's Sponsor